🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
530,76 USD
Máx. histórico
558,88
4 días
Split 2:1 del 24/08/2000
Caída desde máximo
-5,03%
Rango 52 semanas
403,16 – 568,67
Variación hoy
-4,05%
Cierre anterior
553,15
Rango de hoy
529,15 – 561,96
Volumen hoy
2.372.462
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 30,91 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 576,29 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 1 día
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 25/04/1996 | 14,38 | 15,31 | 14,25 | 15,13 | +1,68% | 7,39% | 466.000 |
| 24/04/1996 | 14,50 | 14,88 | 14,13 | 14,88 | +4,39% | 5,17% | 337.200 |
| 23/04/1996 | 13,88 | 15,00 | 13,88 | 14,25 | +2,70% | 8,11% | 500.600 |
| 22/04/1996 | 13,63 | 14,00 | 13,38 | 13,88 | +2,30% | 4,59% | 231.400 |
| 19/04/1996 | 13,63 | 13,75 | 13,38 | 13,56 | -0,46% | 2,75% | 123.800 |
| 18/04/1996 | 13,63 | 13,63 | 13,25 | 13,63 | +0,93% | 2,75% | 50.400 |
| 17/04/1996 | 13,25 | 13,63 | 13,25 | 13,50 | +1,89% | 2,83% | 124.600 |
| 16/04/1996 | 13,31 | 13,75 | 13,25 | 13,25 | +0,00% | 3,76% | 167.000 |
| 15/04/1996 | 13,75 | 13,75 | 13,25 | 13,25 | -2,75% | 3,64% | 285.400 |
| 12/04/1996 | 14,00 | 14,13 | 13,63 | 13,63 | -1,80% | 3,57% | 360.600 |
| 11/04/1996 | 14,25 | 14,25 | 13,88 | 13,88 | -3,48% | 2,63% | 52.400 |
| 10/04/1996 | 15,00 | 15,00 | 14,25 | 14,38 | -2,54% | 5,00% | 120.800 |
| 09/04/1996 | 15,25 | 15,25 | 14,75 | 14,75 | -1,67% | 3,28% | 322.200 |
| 08/04/1996 | 14,13 | 15,31 | 14,13 | 15,00 | +0,84% | 8,41% | 381.800 |
| 04/04/1996 | 15,63 | 15,63 | 14,75 | 14,88 | -2,46% | 5,60% | 230.400 |
| 03/04/1996 | 14,13 | 15,25 | 14,00 | 15,25 | +12,96% | 8,85% | 506.600 |
| 02/04/1996 | 13,38 | 13,50 | 12,75 | 13,50 | +3,85% | 5,61% | 105.200 |
| 01/04/1996 | 13,50 | 13,50 | 13,00 | 13,00 | -1,89% | 3,70% | 100.000 |
| 29/03/1996 | 13,38 | 13,50 | 12,63 | 13,25 | -0,93% | 6,54% | 281.800 |
| 28/03/1996 | 13,63 | 13,63 | 13,38 | 13,38 | -1,38% | 1,83% | 71.200 |
| 27/03/1996 | 13,88 | 14,13 | 13,38 | 13,56 | -2,25% | 5,41% | 99.200 |
| 26/03/1996 | 13,88 | 13,88 | 13,88 | 13,88 | -0,45% | 0,00% | 15.600 |
| 25/03/1996 | 13,88 | 14,38 | 13,88 | 13,94 | -0,45% | 3,60% | 29.800 |
| 22/03/1996 | 13,88 | 14,06 | 13,88 | 14,00 | +0,90% | 1,35% | 33.000 |
| 21/03/1996 | 13,63 | 14,50 | 13,63 | 13,88 | +0,00% | 6,42% | 192.400 |
| 20/03/1996 | 13,13 | 14,00 | 13,13 | 13,88 | +3,26% | 6,67% | 192.400 |
| 19/03/1996 | 14,13 | 14,13 | 13,25 | 13,44 | -5,70% | 6,19% | 706.200 |
| 18/03/1996 | 14,50 | 14,75 | 14,25 | 14,25 | -3,39% | 3,45% | 397.200 |
| 15/03/1996 | 14,63 | 14,88 | 14,50 | 14,75 | +0,00% | 2,56% | 141.200 |
| 14/03/1996 | 14,38 | 14,75 | 14,13 | 14,75 | +2,61% | 4,35% | 69.800 |